First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, David P., Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M. +21 more·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1613493

Cited by (1,001)

Items 201–300 of 1,001

Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi, Antonino Carmelo Tralongo, Francesco Massari, Matteo Lambertini, Veronica Mollica, Alessandro Rizzo, Francesca Comito, Raimondo Di Liello, Salvatore Alfieri, Martina Imbimbo et al. · 2022 · European Journal of Cancer
Chondrosarcoma: biology, genetics, and epigenetics
Warren Allen Chow · 2018 · F1000Research
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Jong Yeob Kim, Andreas Kronbichler, Michael Eisenhut, Sung Hwi Hong, Hans J. van der Vliet, Jeonghyun Kang, Jae Il Shin, Gabriele Gamerith · 2019 · Cancers
Corticosteroids and Cancer Immunotherapy
Rachel S. Goodman, Douglas Buckner Johnson, Justin Micah Balko · 2023 · Clinical Cancer Research
PD-L1 expression testing in non-small cell lung cancer
Cristina Teixidó, Noelia Vilariño, Roxana Reyes, Noemı́ Reguart · 2018 · Therapeutic Advances in Medical Oncology
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Antonino Glaviano, Hannah Lau, Lukas M. Carter, E. Hui Clarissa Lee, Hiu Yan Lam, Elena Okina, Donavan Jia Jie Tan, Wency Tan, Hui Li Ang, Daniela Carbone et al. · 2025 · Journal of Hematology & Oncology
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions
Ross Andrew Soo, Sun Min Lim, Nicholas L. X. Syn, Rebecca Siew Yan Teng, Richie Soong, Tony S.K. Mok, Byoung Chul Cho · 2017 · Lung Cancer
Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
Ivo Buchhalter, Eugen Rempel, Volker Endris, Michael Allgäuer, Olaf Neumann, Anna‐Lena Volckmar, Martina Kirchner, Jonas Leichsenring, Amelie Lier, Moritz von Winterfeld et al. · 2018 · International Journal of Cancer
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out
Claudia Proto, Roberto Ferrara, Diego Signorelli, Giuseppe Lo Russo, Giulia Galli, Martina Imbimbo, Arsela Prelaj, Nicoletta Zilembo, Monica Ganzinelli, L.M. Pallavicini et al. · 2019 · Cancer Treatment Reviews
Emerging therapies for non-small cell lung cancer
Chao Zhang, Natasha B. Leighl, Yi-Long Lung Cancer Wu, Wen‐Zhao Zhong · 2019 · Journal of Hematology & Oncology
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis
Teppei Yamaguchi, Junichi Shimizu, Takaaki Hasegawa, Yoshitsugu Horio, Yoshitaka Inaba, Yasushi Yatabe, Toyoaki Hida · 2018 · Lung Cancer
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
Xiaoying Sun, Raheleh Roudi, Ting Dai, Shangya Chen, Bin Fan, Hongjin Li, Yaqiong Zhou, Min Zhou, Bo Zhu, Chengqian Yin et al. · 2019 · BMC Cancer
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
Diane Damotte, Sarah E. Warren, Jennifer Arrondeau, Pascaline Boudou, Audrey Mansuet‐Lupo, Jérôme Biton, Hanane Ouakrim, Marco Alifano, Claire Gervais, Audrey Bellesœur et al. · 2019 · Journal of Translational Medicine
Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer
Yanhua Tian, Qingqing Li, Zhenlin Yang, Shu Zhang, Jiachen Xu, Zhijie Wang, Hua Bai, Jianchun Duan, Bo Jian Zheng, Wen Li et al. · 2022 · Signal Transduction and Targeted Therapy
Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Xuefei Zhou, Xiangrui Liu, Leaf Huang · 2020 · Advanced Functional Materials
Combining chemotherapy with PD-1 blockade in NSCLC
Matthen Mathew, Thomas Enzler, Catherine A. Shu, Naiyer A. Rizvi · 2018 · Pharmacology & Therapeutics
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, Takeshi Morimoto, Young Hak Kim, Keisuke Tomii, Tadashi Ishida, Masataka Hirabayashi, Satoshi Hara, Manabu Ishitoko et al. · 2018 · Lung Cancer
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
Aixa Elena Soyano, Bhagirathbhai Dholaria, Julian Andres Marin-Acevedo, Nancy N. Diehl, David O. Hodge, Yan Luo, Rami Manochakian, Saranya Chumsri, Alex A. Adjei, Keith L. Knutson et al. · 2018 · Journal for ImmunoTherapy of Cancer
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
Catherine R. Sears, Tobias Peikert, Jennifer D. Possick, Jarushka Naidoo, Mizuki Nishino, Sandip Pravin Patel, Philippe Camus, Mina Gaga, Edward B. Garon, Michael K. Gould et al. · 2019 · American Journal of Respiratory and Critical Care Medicine
The intimate relationship between gut microbiota and cancer immunotherapy
Arielle Elkrief, Lisa Derosa, Laurence Zitvogel, Guido Kroemer, Bertrand Routy · 2018 · Gut Microbes
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade
Guangchuan Wang, Ryan Dz-Wei Chow, Lvyun Zhu, Zhigang Bai, Lupeng Ye, Feifei Zhang, Paul A. Renauer, Matthew B. Dong, Xiaoyun Dai, Xiaoya Zhang et al. · 2020 · Cancer Discovery
Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC
Rakaee, Mehrdad, Adib, Elio, Ricciuti, Biagio, Sholl, Lynette M., Shi, Weiwei, Alessi, Joao V., Cortellini, Alessio, Fulgenzi, Claudia A. M., Viola, Patrizia, Pinato, David J. et al. · 2023 · JAMA Oncology
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Ke Ma, Yali Lu, Shanshan Jiang, Jiangong Tang, Xin Li, Yuyang Zhang · 2018 · Frontiers in Pharmacology
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier · 2021 · International Journal of Molecular Sciences
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Brian J. Sworder, David Matthew Kurtz, Stefan Alig, Matthew Joshua Frank, Navika Shukla, Andrea Garofalo, Charles W. Macaulay, Mohammad Shahrokh Esfahani, Mari N. Olsen, James Hamilton et al. · 2022 · Cancer Cell
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Triparna Sen, Carl Michael Gay, Lauren A. Byers · 2018 · Translational Lung Cancer Research
High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
Dedong Cao, Huilin Xu, Ximing Xu, Tao Guo, Wei Ge · 2019 · OncoImmunology
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Michael A. Harris, Christine J. Hawkins · 2022 · International Journal of Molecular Sciences
The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
Yongfeng Wu, Jinming Xu, Chengli Du, Yihua Wu, Dajing Xia, Wang Lv, Jian Hu · 2019 · Frontiers in Oncology
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
Yun Hua Lee, David Wai-Meng Tai, Connie Yip, Su Pin Choo, Valerie Chew · 2020 · Frontiers in Immunology
Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
Óscar Lapuente-Santana, Maisa N.G. van Genderen, P.A.J. Hilbers, Francesca Finotello, Federica Eduati · 2021 · Patterns
Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors
Matthew Joseph Bott, Jonathan Cools‐Lartigue, Kay See Tan, Joseph Dycoco, Manjit S. Bains, Robert J. Downey, James Guoxian Huang, James M. Isbell, Daniela Molena, Bernard J. Park et al. · 2018 · The Annals of Thoracic Surgery
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui et al. · 2021 · Frontiers in Oncology
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
Scott N. Gettinger, Anna Wurtz, Sarah B. Goldberg, David L. Rimm, Kurt Alex Schalper, Susan M. Kaech, Paula Kavathas, Anne C. Chiang, Rogério Lilenbaum, Daniel A. Zelterman et al. · 2018 · Journal of Thoracic Oncology
Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging
Ziming Du, Jia‐Ren Lin, Rumana Rashid, Zoltan Maliga, Shu Wang, Jon Christopher Aster, Benjamin Izar, Peter Karl Sorger, Sandro Santagata · 2019 · Nature Protocols
The role of neoantigen in immune checkpoint blockade therapy
Ming Yi, Shuang Qin, Weiheng Zhao, Shengnan Yu, Qian Chu, Kongming Wu · 2018 · Experimental Hematology and Oncology
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
Adam Grippin, Christiano Marconi, Sage A. Copling, Nan Li, Chen Braun, Cole Woody, Elliana J. Young, Priti Gupta, Min Wang, Annette Wu et al. · 2025 · Nature
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
Frank Stephen Hodi, Jedd D. Wolchok, Dirk Schadendorf, James Larkin, Georgina Venetia Long, Xiaozhong Qian, Abdel Saci, Tina C. Young, Sujaya Srinivasan, Han Chang et al. · 2021 · Cancer Immunology Research
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape
Yoshiko Takeuchi, Tokiyoshi Tanegashima, Eiichi Sato, Takuma Irie, Atsuo Sai, Kota Itahashi, Shogo Kumagai, Yasuko Tada, Yosuke Togashi, Shohei Koyama et al. · 2021 · Science Immunology
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
Nicolás Gonzalo Núñez, Fiamma Berner, Ekaterina Friebel, Susanne Unger, Nina Wyss, Julia M. Martínez Gómez, Mette-Triin Purde, Rebekka Niederer, Maximilian Porsch, Christa Lichtensteiger et al. · 2023 · Med
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275
Matthew D. Galsky, Abdel Saci, Péter Márton Szabó, G. Celine Han, Gary D. Grossfeld, Sandra Collette, Arlene Odelia Siefker-Radtke, Andrea Necchi, Padmanee Sharma · 2020 · Clinical Cancer Research
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Irene Moya‐Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell · 2018 · Therapeutic Advances in Medical Oncology
The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy
Zihao Xu, Peiyao Li, Li Fan, Minghua Wu · 2018 · Frontiers in Immunology
BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining
Kewei Bi, Xu-Ge Wei, Xiaoxue Qin, Bo Li · 2020 · Frontiers in Oncology
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Solange Peters, Jean-Louis Pujol, Urania G. Dafni, Manuel Dómine, Sanjay Popat, Martin Reck, Jesus Andrade, Annemarie Becker‐Commissaris, Denis Moro‐Sibilot, Alessandra Curioni Fontecedro et al. · 2021 · Annals of Oncology
Role of immune-checkpoint inhibitors in lung cancer
Prantesh Jain, Chhavi Jain, Vamsidhar Velcheti · 2018 · Therapeutic Advances in Respiratory Disease
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
Anastasia Mpakali, Efstratios Stratikos · 2021 · Cancers
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Mengke Niu, Ming Yi, Ning Li, Suxia Luo, Kongming Wu · 2021 · Experimental Hematology and Oncology
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Yuan Cheng, Tao Zhang, Qing Xu · 2021 · MedComm
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study
Kaspar Draaisma, Aikaterini Chatzipli, MARTIN J.B. TAPHOORN, Melissa Kerkhof, Astrid Weyerbrock, Marc Sanson, Ann Hoeben, Slávka Lukacova, Giuseppe Lombardi, Sieger Leenstra et al. · 2019 · Journal of Clinical Oncology
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
Antonio Galvano, Valerio Gristina, Umberto Malapelle, Pasquale Pisapia, Francesco Pepe, Nadia Barraco, Marta Castiglia, Alessandro Perez, Christian Diego Rolfo, Giancarlo Troncone et al. · 2021 · ESMO Open
Cancer metastasis: Molecular mechanisms and clinical perspectives
Sameer Ullah Khan, Kaneez Fatima, Fayaz Ahmad Malik, Halime Kalkavan, Abubakar Wani · 2023 · Pharmacology & Therapeutics
The clinical utility of tumor mutational burden in non-small cell lung cancer
Laurent Greillier, Pascale Tomasini, Fabrice Barlési · 2018 · Translational Lung Cancer Research
Immune checkpoint inhibitors in advanced non–small cell lung cancer
Hazem I. Assi, Alice Oliffson Kamphorst, Nour M. Moukalled, Suresh S. Ramalingam · 2017 · Cancer
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Fumihiro Shoji, Hiroaki Takeoka, Yuka Kozuma, Gouji Toyokawa, Koji Yamazaki, Masao Ichiki, Sadanori Takeo · 2019 · Lung Cancer
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Sara Saab, Hussein Zalzale, Zahraa Rahal, Yara Khalifeh, Ansam F. Sinjab, Humam N. Kadara · 2020 · Frontiers in Immunology
Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials
Fang Yang, Svetomir N. Markovic, Julian R. Molina, Thorvardur Ragnar Halfdanarson, Lance C. Pagliaro, Ashish Vittalrao Chintakuntlawar, Rutian Li, Jia Wei, Lifeng Wang, Baorui Liu et al. · 2020 · JAMA Network Open
Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma
Kai Kang, Fucun Xie, Jinzhu Mao, Yi Bai, Xiang Wang · 2020 · Frontiers in Oncology
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result
Mengmeng Jiang, Dazhen Sun, Yinglong Guo, Yixian Guo, Jie Xiao, Lisheng Wang, Xiuzhong Yao · 2019 · Academic Radiology
Immune checkpoint inhibitors win the 2018 Nobel Prize
Pei‐Wei Huang, John Wen‐Cheng Chang · 2019 · Biomedical Journal
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Current Cancer Drug Targets
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Xueping Wang, Fang Wang, Mengjun Zhong, Yosef Yarden, Liwu Fu · 2020 · Molecular Cancer
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Haiyang Guo, Jun Zhang, Chao Qin, Hang Yan, Tao Liu, Haiyang Hu, Shengjie Tang, Shoujun Tang, Haining Zhou · 2022 · Cells
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Sun Min Lim, Min Hee Hong, Hye Ryun Kim · 2020 · Immune Network
Predictive biomarkers for response to immune checkpoint inhibition
Benjamin Shum, James Larkin, Samra Turajlic · 2021 · Seminars in Cancer Biology
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer
Harper Hubbeling, Emily S. Lebow, Nora Horick, Kelly E. Goodwin, Jessica J. Lin, Kevin S. Oh, Alice Tsang Shaw, William A. Mehan, Helen Alice Shih, Justin F. Gainor · 2018 · Journal of Thoracic Oncology
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Chiara Lazzari, Niki Karachaliou, Alessandra Bulotta, Mariagrazia Viganò, Aurora Mirabile, Elena Brioschi, Mariacarmela Santarpía, Luca Gianni, Rafael Rosell, Vanesa Gregorc · 2018 · Therapeutic Advances in Medical Oncology
Tumor Mutation Burden—From Hopes to Doubts
Alfredo Addeo, Giuseppe Luigi Banna, Glen J. Weiss · 2019 · JAMA Oncology
Mutation-Derived Neoantigens for Cancer Immunotherapy
John C. Castle, Mohamed Uduman, Simarjot Singh Pabla, Robert Benjamin Stein, Jennifer S. Buell · 2019 · Frontiers in Immunology
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
Mingjia Li, Daniel J. Spakowicz, Jarred Thomas Burkart, Sandip Pravin Patel, Marium Husain, Kai He, Erin Marie Bertino, Peter G. Shields, David Paul Carbone, Claire F. Verschraegen et al. · 2019 · Journal of Cancer Research and Clinical Oncology
LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
Niklas Klümper, Damian Johannes Ralser, Emma Bawden, Jenny Landsberg, Romina Zarbl, Glen Kristiansen, Marieta Ioana Toma, Manuel Ritter, Michael Hölzel, Jörg Ellinger et al. · 2020 · Journal for ImmunoTherapy of Cancer
The role of molecular enrichment on future therapies in hepatocellular carcinoma
Jean‐Charles Nault, Peter R. Galle, Jens Uwe Marquardt · 2018 · Journal of Hepatology
Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer
Eugene Muchnik, Kah Poh Loh, Myla S. Strawderman, Allison M. Magnuson, Supriya Gupta Mohile, Vered Estrah, Ronald John Maggiore · 2019 · Journal of the American Geriatrics Society
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
Solange Peters, Rafał Dziadziuszko, Alessandro Morabito, Enriqueta Felip, Shirish M. Gadgeel, Parneet Kaur Cheema, Manuel Cobo, Zoran Gojko Andric, Carlos H. Barrios, Masafumi Yamaguchi et al. · 2022 · Nature Medicine
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer
Natalie I. Vokes, David Liu, Biagio Ricciuti, Elizabeth Jimenez-Aguilar, Hira A. Rizvi, Felix Dietlein, Meng He, Claire A. Margolis, Haitham Elmarakeby, Jeffrey Girshman et al. · 2019 · JCO Precision Oncology
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
Karin M. Knudson, Kristin C. Hicks, Sarah Alter, Jeffrey Schlom, Sofia R. Gameiro · 2019 · Journal for ImmunoTherapy of Cancer
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
Ilaria Alborelli, Katharina Leonards, Sacha I. Rothschild, Laura P Leuenberger, Spasenija Savic Prince, Kirsten D. Mertz, Severin Poechtrager, Martin Buess, Alfred Zippelius, Heinz Philipp Laubli et al. · 2019 · The Journal of Pathology
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
Kaichao Feng, Yang Liu, Yongtian Zhao, Qingming Yang, Liang Dong, Jiejie Liu, Xiang Li, Zhikun Zhao, Qian Mei, Weidong Han · 2020 · Journal for ImmunoTherapy of Cancer
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Han Si, Michael A. Kuziora, Katie Quinn, Elena Helman, Jiabu Ye, Feng Liu, Urban J. Scheuring, Solange Peters, Naiyer A. Rizvi, Philip Z. Brohawn et al. · 2020 · Clinical Cancer Research
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
Jeremy M. O’Connor, Kristen L. Fessele, Jean Steiner, Kathi Seidl-Rathkopf, Kenneth Robert Carson, Nathan Coleman Nussbaum, Emily S. Yin, Kerin B. Adelson, Carolyn Jean Presley, Anne C. Chiang et al. · 2018 · JAMA Oncology
Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
Sharyn I. Katz, Mark Morris Hammer, Stephen Joseph Bagley, Charu Aggarwal, Joshua Michael Bauml, Jeffrey C. Thompson, Arun C. Nachiappan, Charles B. Simone, Corey Jay Langer · 2018 · Journal of Thoracic Oncology
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Elizabeth Stephanie Ahern, Mark John Smyth, William C. Dougall, Michele W.L. Teng · 2018 · Nature Reviews Clinical Oncology
Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models
Roberto R. Rosato, Daniel Dávila‐González, Dong Soon Choi, Wei Ping Qian, Wen Chen, Anthony J. Kozielski, Helen H. Wong, Bhuvanesh Dave, Jenny C. Chang · 2018 · Breast Cancer Research
Pretreatment advanced lung cancer inflammation index ( ALI ) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
Takayuki Shiroyama, Hidekazu Suzuki, Motohiro Tamiya, Akihiro Tamiya, Ayako Tanaka, Norio Okamoto, Kenji Nakahama, Yoshihiko Taniguchi, Shun‐ichi Isa, Takako Inoue et al. · 2017 · Cancer Medicine
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Andrea Botticelli, Concetta Elisa Onesti, Ilaria Grazia Zizzari, Bruna Cerbelli, Paolo Sciattella, Mario Alberto Occhipinti, Michela Roberto, Francesca Romana Di Pietro, Adriana Bonifacino, Michele Ghidini et al. · 2017 · Oncotarget
Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost
Chun-Nan Kuo, Yu‐Ming Liao, Li‐Na Kuo, Hui‐Ju Tsai, Wei‐Chiao Chang, Yun Yen · 2019 · Journal of the Formosan Medical Association
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
Antonino Grassadonia, Isabella Sperduti, Patrizia Vici, Laura Iezzi, Davide Brocco, Teresa Gamucci, Laura Pizzuti, Marcello Maugeri‐Saccà, Paolo Marchetti, Gaetana Cognetti et al. · 2018 · Journal of Clinical Medicine
Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
Jingsi Dong, Bingjie Li, Dan Chi-Chia Lin, Qinghua Zhou, Depei Huang · 2019 · Frontiers in Pharmacology
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Jacques L. Cadranel, Anthony Canellas, Lise Matton, Marie Darrason, A. Parrot, Jean‐Marc Naccache, A. Lavolé, Anne-Marie Ruppert, Vincent Fallet · 2019 · European Respiratory Review
Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy
Gang Shi, Qianmei Yang, Yujing Zhang, Qingyuan Jiang, Yi Lin, Shenshen Yang, Huiling Wang, Lin Cheng, Xin Zhang, Yimin Li et al. · 2018 · Molecular Therapy
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
Albrecht Stenzinger, Volker Endris, Jan Budczies, Sabine Merkelbach‐Bruse, Daniel N. Kazdal, Wolfgang Dietmaier, Nicole Pfarr, Udo Siebolts, Michael Hummel, Sylvia Herold et al. · 2020 · Journal of Thoracic Oncology
The Role of Tumour Metabolism in Cisplatin Resistance
Lude Wang, Xiaoya Zhao, Jianfei Fu, Wenxia Xu, Jianlie Yuan · 2021 · Frontiers in Molecular Biosciences
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer
Muhammad Babar Khan, Jie Lin, Guixiang Liao, Yunhong Tian, Yingying Liang, Rong Li, Mengzhong Liu, Yawei Yuan · 2018 · Medicine
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
Solange Peters, Martin Reck, Egbert Frederik Smit, Tony S.K. Mok, Matthew David Hellmann · 2019 · Annals of Oncology
Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden
Tomoyuki Naito, Hibiki Udagawa, Shigeki Umemura, Tetsuya Sakai, Yoshitaka Zenke, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Masahiro Tsuboi et al. · 2019 · Lung Cancer
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy
Matthen Mathew, Mariam Zade, Nadia Mezghani, Romil D. Patel, Yu Wang, Fatemeh Momen‐Heravi · 2020 · Cancers
Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials
Elvire Pons Tostivint, Aurélien Latouche, Pauline Vaflard, Francesco Ricci, Delphine Loirat, S. Hescot, Marie‐Paule Sablin, Roman Rouzier, Maud T Kamal, Claire Morel et al. · 2019 · JCO Precision Oncology
The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer
Arutha Kulasinghe, Joanna Kapeleris, Rebecca Kimberley, Stephen R. Mattarollo, Erik W. Thompson, Jean Paul Thiery, Liz Kenny, Kenneth John O'Byrne, Chamindie Punyadeera · 2018 · Cancer Medicine
Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer
Robert Pirker · 2019 · Current Opinion in Oncology
Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure
Ziying Lin, Lixia Huang, Shaoli Li, Jincui Gu, Xiaoxian Cui, Yanbin Zhou · 2020 · Scientific Reports